WMT

WMT is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule drugs for oncology and autoimmune diseases. Based in Suzhou, China, the company utilizes a structure-based drug design approach to target high-value biological pathways. Its lead program, WMT-101, is a selective inhibitor of dihydroorotate dehydrogenase (DHODH) currently in Phase 1 clinical development for acute myeloid leukemia (AML). WMT's pipeline also includes several early-stage programs targeting solid tumors and inflammatory conditions. The leadership team consists of industry veterans with extensive experience in global drug R&D, particularly from Eli Lilly. The company is backed by prominent venture capital firms including Qiming Venture Partners and TF Capital.